Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis

Annals of Oncology

Volumn 27, Issue 12, 2016, Pages 2184-2195

  Coyle, C ^a   Cafferty, F H ^a   Vale, C ^a   Langley, R E ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

adjuvant; breast cancer; colorectal cancer; metformin; prostate cancer; repurposing

Indexed keywords

METFORMIN;

ADJUVANT CHEMOTHERAPY; CANCER STAGING; DISEASE FREE SURVIVAL; HUMAN; META ANALYSIS; NEOPLASM; PATHOLOGY;

CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; HUMANS; METFORMIN; NEOPLASM STAGING; NEOPLASMS;

EID: 85012027941     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw410     Document Type: Article

References (79)

1. CRUK. Cancer Research UK Cancer Statistics, All Cancers Combined. http://publications.cancerresearchuk.org/downloads/Product/CS_KF_ALLCANCERS.pdf (10 January 2016, date last accessed).
2. Quaresma, M., Coleman, M.P., Rachet, B., 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based study. Lancet 385 (2015), 1206–1218.
3. Langley, R.E., Burdett, S., Tierney, J.F., et al. Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?. Br J Cancer 105 (2011), 1107–1113.
4. Gilbert, D.C., Vale, C., Haire, R., et al. Repurposing vitamin D as an anticancer drug. Clin Oncol (R Coll Radiol) 28 (2016), 36–41.
5. Coleman, R., Powles, T., Paterson, A., et al. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386 (2015), 1353–1361.
6. Park, H.S., Schoenfeld, J.D., Mailhot, R.B., et al. Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. Ann Oncol 24 (2013), 1427–1434.
7. NICE, National Institute of Health and Care Excellence: Type II Diabetes CG87. 2009.
8. Costello, M., Shrestha, B., Eden, J., et al. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev, 2007, CD005552.
9. Dowling, R.J., Niraula, S., Stambolic, V., Goodwin, P.J., Metformin in cancer: translational challenges. J Mol Endocrinol 48 (2012), R31–R43.
10. Dowling, R.J., Zakikhani, M., Fantus, I.G., et al. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67 (2007), 10804–10812.
11. Fidan, E., Onder Ersoz, H., Yilmaz, M., et al. The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus. Acta Diabetol 48 (2011), 297–302.
12. Dowling, R.J., Goodwin, P.J., Stambolic, V., Understanding the benefit of metformin use in cancer treatment. BMC Med, 9, 2011, 33.
13. Hadad, S., Iwamoto, T., Jordan, L., et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 128 (2011), 783–794.
14. Niraula, S., Dowling, R.J., Ennis, M., et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 135 (2012), 821–830.
15. Hosono, K., Endo, H., Takahashi, H., et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) 3 (2010), 1077–1083.
16. Decensi, A., Puntoni, M., Goodwin, P., et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res 3 (2010), 1451–1461.
17. Gandini, S., Puntoni, M., Heckman-Stoddard, B.M., et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res 7 (2014), 867–885.
18. Zhang, P., Li, H., Tan, X., et al. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol 37 (2013), 207–218.
19. Soranna, D., Scotti, L., Zambon, A., et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 17 (2012), 813–822.
20. Noto, H., Goto, A., Tsujimoto, T., Noda, M., Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One, 7, 2012, e33411.
21. Zhang, Z.J., Li, S., The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 16 (2014), 707–710.
22. Lega, I.C., Shah, P.S., Margel, D., et al. The effect of metformin on mortality following cancer among patients with diabetes. Cancer Epidemiol Biomarkers Prev 23 (2014), 1974–1984.
23. Yin, M., Zhou, J., Gorak, E.J., Quddus, F., Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis. Oncologist 18 (2013), 1248–1255.
24. Mei, Z.B., Zhang, Z.J., Liu, C.Y., et al. Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis. PLoS One, 9, 2014, e91818.
25. Stopsack, K.H., Ziehr, D.R., Rider, J.R., Giovannucci, E.L., Metformin and prostate cancer mortality: a meta-analysis. Cancer Causes Control 27 (2016), 105–113.
26. Raval, A.D., Thakker, D., Vyas, A., et al. Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 18 (2015), 110–121.
27. Yu, H., Yin, L., Jiang, X., et al. Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies. PLoS One, 9, 2014, e116327.
28. Xu, H., Chen, K., Jia, X., et al. Metformin use is associated with better survival of breast cancer patients with diabetes: a meta-analysis. Oncologist 20 (2015), 1236–1244.
29. Higurashi, T., Hosono, K., Takahashi, H., et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol 17 (2016), 475–483.
30. Clarke, M., Brice, A., Chalmers, I., Accumulating research: a systematic account of how cumulative meta-analyses would have provided knowledge, improved health, reduced harm and saved resources. PLoS One, 9, 2014, e102670.
31. Jones, A.P., Conroy, E., Williamson, P.R., et al. The use of systematic reviews in the planning, design and conduct of randomised trials: a retrospective cohort of NIHR HTA funded trials. BMC Med Res Methodol, 13, 2013, 50.
32. PROSPERO (International Prospective Register of Systematic Reviews). http://www.crd.york.ac.uk/prospero/ (January 2016, date last accessed).
33. GWells, BShea, DO'Connell. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.
34. Parmar, M.K., Torri, V., Stewart, L., Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17 (1998), 2815–2834.
35. Tierney, J.F., Stewart, L.A., Ghersi, D., et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 8, 2007, 16.
36. Williamson, P.R., Smith, C.T., Hutton, J.L., Marson, A.G., Aggregate data meta-analysis with time-to-event outcomes. Stat Med 21 (2002), 3337–3351.
37. DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin Trials 7 (1986), 177–188.
38. Spillane, S., Bennett, K., Sharp, L., Barron, T.I., A cohort study of metformin exposure and survival in patients with stage I–III colorectal cancer. Cancer Epidemiol Biomarkers Prev 22 (2013), 1364–1373.
39. Lee GE, A.T., Lim, K.H., Tan, W.S., et al. Examining the effects of metformin on survival outcome in stage II/III colorectal cancer patients with diabetes mellitus. J Clin Oncol, 30, 2012 abstr 3589.
40. Lee, J.H., Kim, T.I., Jeon, S.M., et al. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer 131 (2012), 752–759.
41. Singh, P.P., Shi, Q., Foster, N.R., et al. Relationship between metformin use and recurrence and survival in patients (pts) with resected stage III colon cancer (CC) receiving adjuvant chemotherapy: Results from NCCTG N0147 (Alliance). ASCO Meeting Abstr, 33, 2015, 3531.
42. Zanders, M.M., van Herk-Sukel, M.P., Vissers, P.A., et al. Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another?. Br J Cancer 113 (2015), 403–410.
43. Allott, E.H., Abern, M.R., Gerber, L., et al. Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis 16 (2013), 391–397.
44. Kaushik, D., Karnes, R.J., Eisenberg, M.S., et al. Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol 32 (2014), 43.e41–43.e47.
45. Rieken, M., Kluth, L.A., Xylinas, E., et al. Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. World J Urol 32 (2014), 999–1005.
46. Spratt, D.E., Zhang, C., Zumsteg, Z.S., et al. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 63 (2013), 709–716.
47. Margel, D., Urbach, D.R., Lipscombe, L.L., et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 31 (2013), 3069–3075.
48. Zannella, V.E., Dal Pra, A., Muaddi, H., et al. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin Cancer Res 19 (2013), 6741–6750.
49. Danzig, M.R., Kotamarti, S., Ghandour, R.A., et al. Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes. Prostate Cancer Prostatic Dis 18 (2015), 63–68.
50. Taira, A.V., Merrick, G.S., Galbreath, R.W., et al. Metformin is not associated with improved biochemical free survival or cause-specific survival in men with prostate cancer treated with permanent interstitial brachytherapy. J Contemp Brachytherapy 6 (2014), 254–261.
51. Oppong, B.A., Pharmer, L.A., Oskar, S., et al. The effect of metformin on breast cancer outcomes in patients with type 2 diabetes. Cancer Med 3 (2014), 1025–1034.
52. Bayraktar, S., Hernadez-Aya, L.F., Lei, X., et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 118 (2012), 1202–1211.
53. Lega, I.C., Austin, P.C., Gruneir, A., et al. Association between metformin therapy and mortality after breast cancer: a population-based study. Diabetes Care 36 (2013), 3018–3026.
54. Rieken, M., Xylinas, E., Kluth, L., et al. Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. BJU Int 112 (2013), 1105–1112.
55. Rieken, M., Xylinas, E., Kluth, L., et al. Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. Urol Oncol 32 (2014), 49.e7–49.e14.
56. Rieken, M., Xylinas, E., Kluth, L., et al. Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur J Surg Oncol 40 (2014), 113–120.
57. Kwon, M., Roh, J.L., Song, J., et al. Effect of metformin on progression of head and neck cancers, occurrence of second primary cancers, and cause-specific survival. Oncologist 20 (2015), 546–553.
58. Thompson, C., Wang, M., Sanaiha, Y., et al. An analysis of the potential benefits of metformin on disease recurrence in oral and oropharyngeal squamous cell carcinoma. J Cancer Ther 4 (2013), 961–965.
59. Hakimi, A.A., Chen, L., Kim, P.H., et al. The impact of metformin use on recurrence and cancer-specific survival in clinically localized high-risk renal cell carcinoma. Can Urol Assoc J 7 (2013), E687–E691.
60. Psutka, S.P., Boorjian, S.A., Lohse, C.M., et al. The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma. Urol Oncol 33 (2015), 67e15–67e23.
61. Ambe, C., Mahipal, A., Fulp, W.J., et al. Effect of metformin use on the survival outcomes in diabetic patients with resectable pancreatic cancer: a single-institutional experience and meta-analysis. ASCO Meeting Abstr, 33, 2015, 465.
62. Fortune-Greeley, A.K., Williams, C.D., Paulus, J.K., Kelley, M.J., Association between metformin (M) use and survival among non-small cell lung cancer (NSCLC) patients (pts). ASCO Meeting Abstr, 32, 2014, 7568.
63. Ko, E.M., Walter, P., Jackson, A., et al. Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol 132 (2014), 438–442.
64. Lee, C.K., Jung, M., Jung, I., et al. Cumulative metformin use and its impact on survival in gastric cancer patients after gastrectomy. Ann Surg 263 (2016), 96–102.
65. Ruderman, N.B., Carling, D., Prentki, M., Cacicedo, J.M., AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest 123 (2013), 2764–2772.
66. Alberti, K.G., Eckel, R.H., Grundy, S.M., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120 (2009), 1640–1645.
67. Giovannucci, E., Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 86 (2007), s836–s842.
68. Shen, Z., Ye, Y., Bin, L., et al. Metabolic syndrome is an important factor for the evolution of prognosis of colorectal cancer: survival, recurrence, and liver metastasis. Am J Surg 200 (2010), 59–63.
69. Bosco, C., Crawley, D., Adolfsson, J., et al. Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis. PLoS One, 10, 2015, e0117344.
70. Zannella, V.E., Cojocari, D., Hilgendorf, S., et al. AMPK regulates metabolism and survival in response to ionizing radiation. Radiother Oncol 99 (2011), 293–299.
71. Zannella, V.E., Pra, A.D., Muaddi, H., et al. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin Cancer Res 19 (2013), 6741–6750.
72. Suissa, S., Azoulay, L., Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 35 (2012), 2665–2673.
73. Burn, J., Gerdes, A.M., Macrae, F., et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378 (2011), 2081–2087.
74. Cook, N.R., Lee, I.M., Zhang, S.M., et al. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 159 (2013), 77–85.
75. Rothwell, P.M., Wilson, M., Elwin, C.E., et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376 (2010), 1741–1750.
76. Jeon, J.Y., Jeong, D.H., Park, M.G., et al. Impact of diabetes on oncologic outcome of colorectal cancer patients: colon vs. rectal cancer. PLoS One, 8, 2013, e55196.
77. Oh, J.J., Hong, S.K., Lee, S., et al. Diabetes mellitus is associated with short prostate-specific antigen doubling time after radical prostatectomy. Int Urol Nephrol 45 (2013), 121–127.
78. Bodmer, M., Meier, C., Krahenbuhl, S., et al. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33 (2010), 1304–1308.
79. Col, N.F., Ochs, L., Springmann, V., et al. Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat 135 (2012), 639–646.